BMRN

BioMarin Pharmaceutical Inc

$56.38+$0.38+0.68%Price as of Oct 29, 2026, 9:31 AM ET

Key stats

Market cap: 10.9B
Open: —
Day range: —
52-week range: $49.26 – $70.98
Volume: 16.1K
Avg volume: 2.47M

Earnings

Q3 FY26Upcoming

Expected$0.20

Q2 FY26

Actual$0.23

Q1 FY26

Actual$0.54

Q4 FY25

Actual$-0.23

About

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Employees: 3,221
Headquarters: Novato, CA